This incisive management report analyzes the impact of the UK health reforms on a domestic level and in the context of a global trend towards attaining more cost-effective healthcare through pharmacoeconomic evaluation. In doing so, the report details the current use and future scope of pharmacoeconomics across major pharmaceutical markets and forecasts the commercial implications of pharmacoeconomics on pricing and reimbursement within seven major markets, including France, Germany, Japan and the US, to 2005.
